Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen
Marie Robin,Olivier Nibourel,Martin Tournaire,David Michonneau,Claude Preudhomme,Marie Verbanck,Aliénor Xhaard,Lionel Adès,Flore Sicre de Fontbrune,Marie Sébert,Pierre Fenaux,Gérard Socié,Régis Peffault de Latour,Emmanuel Curis
DOI: https://doi.org/10.1038/s41409-024-02314-2
2024-05-24
Bone Marrow Transplantation
Abstract:Somatic mutations in myelodysplastic syndrome (MDS) are increasingly considered to assess patients' prognosis. IPSS-M, a recently developed and validated (including after allogeneic hematopoietic stem cell transplantation (HSCT)) molecular international score system with genetic alteration, stratifies six prognostic groups [1, 2]. IPSS-M, like non-molecular IPSS, may help to estimate post-HSCT outcome and to guide transplantation indication [3,4,5]. Somatic mutations screening and monitoring may also be crucial markers of minimal measurable residual disease (MRD), especially after HSCT when the aim is complete remission and cure. Gene detection by next generation sequencing (NGS) after transplantation was reported by Duncavage and colleagues in 90 MDS patients transplanted after myeloablative or reduced-intensity conditioning regimen (RIC), confirming the feasibility of NGS MRD monitoring in MDS patients: [6] Post-transplantation NGS-MRD positivity predicted relapse, especially after RIC. Another multicenter study reported MRD monitoring by digital droplet PCR (ddPCR) targeting pre-transplantation mutations in 266 MDS patients, mainly receiving a treosulfan-based conditioning regimen [7]: MRD was positive 70 days (median) before morphological relapse and significantly associated with relapse-free survival and overall survival (OS). However, standard MRD detection in MDS is still under investigation; screening a MDS-gene panel may be an option if the detection sensibility is high enough [8]. The present study analyzed the potential impact on the outcomes of somatic mutations detected before and after transplantation by NGS and highly-sensitive ddPCR in a cohort of 106 MDS patients transplanted after a RIC. Methods are available in Supplementary data. This is a single-center retrospective study conducted according to the declaration of Helsinki. All patients signed an informed consent form about sharing their clinical and biological data on a local database and for molecular analysis. The study was approved by the Ethical committee Île-de-France (2015/69NICB). This is a single-center retrospective study conducted according to the declaration of Helsinki. All patients signed an informed consent form about sharing their clinical and biological data on a local database and for molecular analysis. The study was approved by the Ethical committee Île-de-France (2015/69NICB). We only included patients who received a RIC, where MRD+ has been reported as predictive of relapse mainly after RIC [9]. In our cohort, most patients had MDS with ( n = 63) or without ( n = 15) excess blast; 10 had chronic myelomonocytic leukemia and 18 MDS transformed into AML before transplantation. Patient characteristics are available in Table 1S. Eighty-eight (83%) patients had at least one somatic mutation detectable before transplantation using a 36-genes panel. IPSS-M strongly correlated with IPSS (linear correlation, r = 0.6063, p < 0.0001), IPSS-R ( r = 0.7422, p < 0.0001), and IPSS-R cytogenetics ( r = 0.6017, p < 0.0001). Pre-graft, none of the 36 patients tested had mutation clearance, regardless of the treatment received. Eleven patients had a stable genetic profile (including no detected mutation), 10 patients enriched their profile by at least one additional mutation, and 15 patients had a different mutational profile (initial mutations not all found, new molecular alterations), Fig. 1S. This confirms that chemotherapy or demethylating agents not often eradicate malignant clones, and that genetic profile changes over time in these patients [10].
oncology,immunology,hematology,transplantation